- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Cidofovir.
Displaying page 1 of 1.
EudraCT Number: 2012-001612-34 | Sponsor Protocol Number: GESIDA-7412 | Start Date*: 2013-02-18 |
Sponsor Name:Fundación SEIMC-GESIDA | ||
Full Title: A prostective, with one site, open-label not controled trial, for the observation of treatment with CIDOFOVIR 1%, 3 nights per week, during 4 weeks, of Anal Intraephitelial Neoplasia, high level, i... | ||
Medical condition: Intraephitelial Anal Neoplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001730-18 | Sponsor Protocol Number: TreatAIN | Start Date*: 2019-09-27 |
Sponsor Name:Fundación Hospital Vall d'Hebron- Institut de Recerca | ||
Full Title: Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepi... | ||
Medical condition: High-grade anal intraepithelial neoplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004725-13 | Sponsor Protocol Number: SHP620-303 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Shire ViroPharma Incorporated | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients... | ||||||||||||||||||
Medical condition: CMV infections resistant or refractory in transplant patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) AT (Completed) HR (Completed) IT (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023271-26 | Sponsor Protocol Number: MI-CI-C02 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Mithra Pharmaceuticals SA | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl... | |||||||||||||
Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003984-37 | Sponsor Protocol Number: CMX001-211 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Chimerix, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia | |||||||||||||
Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004240-30 | Sponsor Protocol Number: AIT-MULTIVIR-01 | Start Date*: 2014-06-18 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-sp... | |||||||||||||
Medical condition: Immune deficiency after allogeneic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003831-31 | Sponsor Protocol Number: 8228-001 | Start Date*: 2014-04-23 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | ||
Full Title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infect... | ||
Medical condition: Clinically significant CMV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) LT (Completed) IT (Completed) FI (Completed) AT (Completed) ES (Completed) BE (Completed) PL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024247-32 | Sponsor Protocol Number: 1263-203 | Start Date*: 2012-03-09 | ||||||||||||||||
Sponsor Name:VIROPHARMA INCORPORATED | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WH... | ||||||||||||||||||
Medical condition: CMV INFECTIONS IN TRANSPLANT RECIPIENTS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) ES (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002492-17 | Sponsor Protocol Number: VISIT-V2 | Start Date*: 2016-06-17 | |||||||||||
Sponsor Name:St. Anna Kinderkrebsforschung | |||||||||||||
Full Title: Treatment of adenovirus and cytomegalovirus infection post human allogeneic stem cell transplantation with short-term expanded virus-specific T cells | |||||||||||||
Medical condition: Patients undergoing allogeneic HSCT undergo weekly screening for HAdV and CMV PCR. In case of viraemia ≥ 100 copies/ml PB preemptive antiviral with either Gancyclovir or Cidofovir conform to the ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004795-35 | Sponsor Protocol Number: CMX001-301 | Start Date*: 2014-06-02 | |||||||||||
Sponsor Name:Chimerix, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection ... | |||||||||||||
Medical condition: Cytomegalovirus (CMV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004940-27 | Sponsor Protocol Number: AIC316-03-II-01(Phase3) | Start Date*: 2022-01-05 |
Sponsor Name:AiCuris Anti-infective Cures GmbH | ||
Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ... | ||
Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001735-39 | Sponsor Protocol Number: CMX001-999 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Chimerix, Inc | |||||||||||||
Full Title: An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of A... | |||||||||||||
Medical condition: Treatment of adenovirus infections in high-risk pediatric allogeneic hematopoietic cell transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed) NL (Prematurely Ended) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
